1H-Imidazole-5-carboxaldehyde, 2-butyl-4-chloro-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
| Title | Journal |
|---|---|
| CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome? | Hypertension (Dallas, Tex. : 1979) 20091001 |
| Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference. | Hypertension (Dallas, Tex. : 1979) 20091001 |
| Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. | Hypertension (Dallas, Tex. : 1979) 20091001 |
| Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. | Hypertension (Dallas, Tex. : 1979) 20091001 |
| EXP3179 inhibits collagen-dependent platelet activation via glycoprotein receptor-VI independent of AT1-receptor antagonism: potential impact on atherothrombosis. | Arteriosclerosis, thrombosis, and vascular biology 20070501 |
| Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. | Hypertension (Dallas, Tex. : 1979) 20060301 |
| Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179. | Circulation 20050920 |
| Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. | Journal of medicinal chemistry 20030605 |